← Back to News

Shasqi presents Phase 2a results of SQ3370 in STS patients at ASCO 2024

June 1, 2024

Shasqi presents results from a Phase 2a study of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced STS patients at the 2024 Annual Clinical Society of Oncology (ASCO) meeting in Chicago.

View the presented poster here

Want to stay up to date on our news? 
Follow us on LinkedIn